New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment
— New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment
by Ian Ingram, Managing Editor, MedPage Today
May 18, 2026
• 2 min read
The FDA on Friday approved two new trastuzumab deruxtecan (T-DXd; Enhertu) indications for treating early-stage breast cancer patients with HER2-positive disease.
The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer.
Enhertu’s market conquest is continuing apace. | Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA…
The FDA has approved atezolizumab and atezolizumab with hyaluronidase-tqjs as adjuvant treatment for certain adults with muscle…
Also known as Ziihera, the antibody treatment targets a protein called HER2, which stimulates tumour growth. It works by…
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug…
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche’s…
